Literature DB >> 10812241

Expression of cyclin-dependent kinase inhibitor p15(INK4B) during normal and leukemic myeloid differentiation.

L Teofili1, R Morosetti, M Martini, R Urbano, R Putzulu, S Rutella, L Pierelli, G Leone, L M Larocca.   

Abstract

OBJECTIVE: Expression of the cyclin-dependent kinase inhibitor p15(INK4B) frequently is altered in myeloid malignancies. We previously demonstrated that p15(INK4B) is expressed in normal myeloid cells. The aim of this study was to investigate whether p15(INK4B) expression is restricted to the granulomonocytic lineage and to evaluate its modulation during normal and leukemic myeloid differentiation.
MATERIALS AND METHODS: Normal CD34(+) cells were cultured in serum-free media to obtain granulomonocytic, erythroid, or megakaryocytic unilineage differentiation. NB4 promyelocytic cell line and fresh leukemic blasts from seven patients with acute promyelocytic leukemia were cultured with all-trans retinoic acid. At different times of culture, cell samples were collected to evaluate p15(INK4B) by semiquantitative reverse transcriptase polymerase chain reaction.
RESULTS: p15(INK4B) mRNA was found during granulomonocytic and megakaryocytic, but not erythroid, differentiation. In the granulomonocytic lineage, p15(INK4B) was detectable when the majority of cells were at the promyelocytic stage and increased progressively in more mature elements. In the megakaryocytic lineage, p15(INK4B) was expressed in the early phase of differentiation, before megakaryoblasts had appeared, and was mantained throughout the time of culture. NB4 cell line and five of seven leukemic samples displayed undetectable or very low level of p15(INK4B) that rapidly increased during retinoic acid-induced differentiation. Two leukemic samples (both collected from two patients developing all-trans retinoic acid syndrome) showed high basal levels of p15(INK4B), which was not modified by retinoic acid treatment.
CONCLUSIONS: p15(INK4B) upregulation occurs specifically during normal granulomonocytic and megakaryocytic commitment. In acute promyelocytic leukemic blasts, p15(INK4B), which is detectable at a very low level, is promptly increased by retinoic acid. In contrast, two acute promyelocytic leukemia samples obtained from patients who developed all-trans retinoic acid syndrome showed high basal levels of p15(INK4B) that did not increase further during all-trans retinoic acid-induced differentiation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10812241     DOI: 10.1016/s0301-472x(00)00139-9

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  5 in total

1.  Tumor suppressor ASXL1 is essential for the activation of INK4B expression in response to oncogene activity and anti-proliferative signals.

Authors:  Xudong Wu; Ida Holst Bekker-Jensen; Jesper Christensen; Kasper Dindler Rasmussen; Simone Sidoli; Yan Qi; Yu Kong; Xi Wang; Yajuan Cui; Zhijian Xiao; Guogang Xu; Kristine Williams; Juri Rappsilber; Casper Kaae Sønderby; Ole Winther; Ole N Jensen; Kristian Helin
Journal:  Cell Res       Date:  2015-10-16       Impact factor: 25.617

Review 2.  Targeting FLT3 to treat leukemia.

Authors:  Heiko Konig; Mark Levis
Journal:  Expert Opin Ther Targets       Date:  2014-09-18       Impact factor: 6.902

3.  CD93 Marks a Non-Quiescent Human Leukemia Stem Cell Population and Is Required for Development of MLL-Rearranged Acute Myeloid Leukemia.

Authors:  Masayuki Iwasaki; Michaela Liedtke; Andrew J Gentles; Michael L Cleary
Journal:  Cell Stem Cell       Date:  2015-09-18       Impact factor: 24.633

4.  Azacytidine (Vidaza(R)) in the treatment of myelodysplastic syndromes.

Authors:  Kavita Raj; Ghulam J Mufti
Journal:  Ther Clin Risk Manag       Date:  2006-12       Impact factor: 2.423

5.  p15Ink4b Loss of Expression by Promoter Hypermethylation Adds to Leukemogenesis and Confers a Poor Prognosis in Acute Promyelocytic Leukemia Patients.

Authors:  Shahid M Baba; Niyaz A Azad; Zafar A Shah; Arshad A Pandith; Aleem Jan; Sheikh A Aziz
Journal:  Cancer Res Treat       Date:  2016-12-05       Impact factor: 4.679

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.